Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan [Yahoo! Finance]
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
PALO ALTO, Calif., March 30, 2026 BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that real-world evidence generated from Guardant's InfinityAI contributed to the recent approval of ENHERTU® (trastuzumab deruxtecan), developed and commercialized by Daiichi Sankyo (TSE:4568) in Japan, for the treatment of patients with HER2-positive ( HER2 [ ERBB2 ] gene amplification or immunohistochemistry [IHC] 3+) advanced or recurrent solid cancers refractory or intolerant to standard treatments. This approval, granted by Japan's Ministry of Health, Labour and Welfare (MHLW), was supported by data from the HERALD, DESTINY-PanTumor02, DESTINY-CRC02 and DESTINY-Lung01 clinical trials and supplemental real-world evidence (RWE) generated using the real-world data platform from InfinityAI, Guardant Health's artificial intelligence platform. HER2 amplification is well characterized in breast cancer but patient identification and evidence cont
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in JapanBusiness Wire
- Why Guardant Health (GH) Stock Is Falling Today [Yahoo! Finance]Yahoo! Finance
- Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data [Yahoo! Finance]Yahoo! Finance
- Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World DataPR Newswire
- Franklin DynaTech Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
GH
Earnings
- 2/19/26 - Beat
GH
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/23/26 - Form 4
- 3/19/26 - Form 4
- GH's page on the SEC website